This session will discuss current treatment options for rare factor deficiencies and platelet dysfunctions. It will also provide practical tips about what information will foster an effective discussion with your hematology care provider about your…
The new VWD guidelines were published in 2020 and heavily integrate the patient voice. But how can you use these in your conversations with healthcare professionals? This session will take a deeper dive into the specific recommendations, where…
Musculoskeletal ultrasound has gradually become a staple in many hemophilia treatment centers. This unique tool is used not only to detect bleeding episodes but also to follow joint health over years. In this session, we will talk about how MSKUS…
Research generates the evidence needed to improve treatment, care and quality of life. Studies are conducted in phases: identify a topic, develop the research question, design the methods, collect information, analyze the results, and share what was…
NBDF has taken the lead on an initiative to develop a National Research Blueprint (NRB), a community-driven journey to shape the future of research together with researchers, the HTC interdisciplinary team, non-profit organizations, government, and…
NHF leadership opens the 2022 Bleeding Disorders Conference with scripted remarks.
This session will apply a psychosocial lens to PTSD and chronic pain by exploring the connection between the two conditions and uncovering potential pain management and coping strategies.
This session explores the risks and realities of substance abuse issues in the bleeding disorders community. Participants will learn strategies to recognize, understand and support those living with substance abuse issues.
Treating hemophilia with an inhibitor is never a one-size-fits-all situation. During this session, experts will discuss past, current, and future advancement options for treating hemophilia with inhibitors along with hot research topics.
Community experts will discuss clinical research studies and why they are essential to the ultra-rare bleeding disorders community.